The First And Only IPL FDA Approved For Dry Eye Management

OptiLight by Lumenis is a light-based, non-invasive treatment done in the area below the eyes to manage dry eye. The first and only IPL FDA-approved for dry eye management. The treatment is safe, gentle, and is backed by More Than 20 Clinical Studies.

OptiLight with Lumenis patented Optimal Pulse Technology uses precise, intense broad spectrum light to address the inflammation – one of the key underlining factors in dry eye disease due to MGD. OptiLight was specifically developed to reach the delicate contours of the treated area safely, effectively and gently. OptiLight sets new treatment standards and helps patients to regain health, control and joy.

How Does It Work?

OptiLight uses precise pulses of light to reduce the inflammation that is typically associated with dry eye disease, improve tear break-up time, and increase meibomian gland functionality.

This application can significantly relieve dry eye indicators and has a multi-factorial effect, including:

  • Increasing tear break-up time

  • Reducing the amount of demodex mites and bacteria living around your eyes

  • Eliminating blood vessels that contribute to inflammation, like ocular rosacea

  • Improving meibomian gland functionality

Elevating Dry Eye Management

Backed by numerous clinical studies, OptiLight’s novel optimal pulse technology (OPT) provides a transformative, safe, and efficacious way to improve Dry Eye disease due to MGD. The way we treat your eyes is the way we want you to feel; safe, with control, and precision. Optimal results in just a few short sessions • A course of treatment typically includes 4 sessions spaced 2-4 weeks apart. • Each session usually takes only 10-15 minutes. • During the treatment your practitioner will apply a coupling gel on the treatment area and cover your eyes with shields. • You may experience a warm sensation as light is applied to the skin, the treatment is gentle with minimum discomfort. • OptiLight is often followed by Meibomian Glands expression.